This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yu, J. Articles by Hatano, Y. Search for Related Content PubMed PubMed Citation Articles by Yu, J. Articles by Hatano, Y. Related Collections Cardiovascular Pharmacology

---

CARDIOVASCULAR ANESTHESIA

The Inhibitory Effects of Sevoflurane on Angiotensin II- Induced, p44/42 Mitogen-Activated Protein Kinase-Mediated Contraction of Rat Aortic Smooth Muscle

Jingui Yu, MD^*, Kazuhiro Mizumoto, MD^*, Yasuyuki Tokinaga, MD^*, Koji Ogawa, MD, and Yoshio Hatano, MD^*

*Department of Anesthesiology and Surgical Operating Center, Wakayama Medical University, Wakayama City, Japan

Address correspondence and reprint requests to Yoshio Hatano, MD, Department of Anesthesiology, Wakayama Medical University, 811-1 Kimiidera, Wakayama City, 641-0012, Japan. Address e-mail to yhatano{at}wakayama-med.ac.jp.

Sevoflurane dilates blood vessels and reduces arterial blood pressure in a dose-dependent manner. Angiotensin II (Ang II) is one of the primary regulators of vascular tension and arterial blood pressure, and the p44/42 mitogen-activated protein kinases (p44/42 MAPK) are involved in Ang II-mediated vascular smooth muscle contraction. We designed this study to examine the effects of sevoflurane on Ang II-induced, p44/42 MAPK-mediated contraction of rat aortic smooth muscle. The effects of the p44/42 MAPK kinase (MEK1/2) inhibitor, PD 098059 (10^–5 molar [M], 5 x 10^–5 M and 10^–4 M), and sevoflurane (1.7%, 3.4%, and 5.1%) on Ang II-induced contraction and p44/42 MAPK phosphorylation were tested in rat aortic smooth muscle, using isometric force measurement and Western blot analysis, respectively. Ang II induced both a transient contractile response and phosphorylation of p44/42 MAPK, which were significantly attenuated by PD 098059 (P < 0.05–0.01). Sevoflurane inhibited Ang II-induced contractile response in a dose-dependent manner (P < 0.05 and 0.01 in response to 3.4% and 5.1% sevoflurane, respectively). Sevoflurane also dose-dependently depressed Ang II-elicited p44/42 MAPK phosphorylation (P < 0.01 in response to 3.4% and 5.1% sevoflurane). These results suggest that the inhibitory effect of sevoflurane on Ang II-induced vasoconstriction is, at least in part, caused by the inhibition of the p44/42 MAPK-mediated signaling pathway.

This article has been cited by other articles:

				A. Ishikawa, K. Ogawa, Y. Tokinaga, N. Uematsu, K. Mizumoto, and Y. Hatano The Mechanism Behind the Inhibitory Effect of Isoflurane on Angiotensin II-Induced Vascular Contraction Is Different from That of Sevoflurane Anesth. Analg., July 1, 2007; 105(1): 97 - 102. [Abstract] [Full Text] [PDF]

				T. A. Khan, C. Bianchi, M. Ruel, J. Feng, and F. W. Sellke Differential effects on the mesenteric microcirculatory response to vasopressin and phenylephrine after cardiopulmonary bypass J. Thorac. Cardiovasc. Surg., March 1, 2007; 133(3): 682 - 688. [Abstract] [Full Text] [PDF]